Header

UZH-Logo

Maintenance Infos

Tumor-associated edema in brain cancer patients: pathogenesis and management


Roth, P; Regli, L; Tonder, M; Weller, M (2013). Tumor-associated edema in brain cancer patients: pathogenesis and management. Expert Review of Anticancer Therapy, 13(11):1319-1325.

Abstract

The long-term treatment of peritumoral edema remains a major challenge in clinical neuro-oncology. Steroids have been and will remain the backbone of any anti-edematous therapy because of their striking activity, convenient oral administration and also because of their cost-effectiveness. Their side effects, however, can compromise quality of life, particularly upon continuous administration. Therapeutic alternatives which may replace or - at least - help to reduce the steroid dose are limited. However, with the development of new agents such as corticorelin acetate, there is a hope that steroid-induced side effects can be delayed and reduced. The administration of anti-angiogenic agents with steroid-sparing effects, for example, bevacizumab, is limited due to their costs. Increased knowledge on boswellic acids and cyclooxygenase-2 inhibitors which are available for clinical application may help to exploit their anti-edema activity more efficiently in the future.

Abstract

The long-term treatment of peritumoral edema remains a major challenge in clinical neuro-oncology. Steroids have been and will remain the backbone of any anti-edematous therapy because of their striking activity, convenient oral administration and also because of their cost-effectiveness. Their side effects, however, can compromise quality of life, particularly upon continuous administration. Therapeutic alternatives which may replace or - at least - help to reduce the steroid dose are limited. However, with the development of new agents such as corticorelin acetate, there is a hope that steroid-induced side effects can be delayed and reduced. The administration of anti-angiogenic agents with steroid-sparing effects, for example, bevacizumab, is limited due to their costs. Increased knowledge on boswellic acids and cyclooxygenase-2 inhibitors which are available for clinical application may help to exploit their anti-edema activity more efficiently in the future.

Statistics

Citations

2 citations in Web of Science®
10 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

217 downloads since deposited on 14 Nov 2013
116 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurosurgery
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2013
Deposited On:14 Nov 2013 11:52
Last Modified:07 Dec 2017 23:38
Publisher:Expert Reviews
ISSN:1473-7140
Publisher DOI:https://doi.org/10.1586/14737140.2013.852473
PubMed ID:24152171

Download

Download PDF  'Tumor-associated edema in brain cancer patients: pathogenesis and management'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 110kB
View at publisher